231 related articles for article (PubMed ID: 18434636)
1. Other endpoints in screening studies for soft tissue sarcomas.
Verweij J
Oncologist; 2008; 13 Suppl 2():27-31. PubMed ID: 18434636
[TBL] [Abstract][Full Text] [Related]
2. Selection of response criteria for clinical trials of sarcoma treatment.
Schuetze SM; Baker LH; Benjamin RS; Canetta R
Oncologist; 2008; 13 Suppl 2():32-40. PubMed ID: 18434637
[TBL] [Abstract][Full Text] [Related]
3. Response assessment in clinical trials: implications for sarcoma clinical trial design.
Jaffe CC
Oncologist; 2008; 13 Suppl 2():14-8. PubMed ID: 18434633
[TBL] [Abstract][Full Text] [Related]
4. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
5. Endpoints for assessing drug activity in clinical trials.
Pazdur R
Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
[TBL] [Abstract][Full Text] [Related]
6. New therapies in soft tissue sarcoma.
Vincenzi B; Frezza AM; Santini D; Tonini G
Expert Opin Emerg Drugs; 2010 Jun; 15(2):237-48. PubMed ID: 20465449
[TBL] [Abstract][Full Text] [Related]
7. SARC-CTOS imaging symposium: introduction to the problem from a clinical perspective.
Benjamin RS
Oncologist; 2008; 13 Suppl 2():1-3. PubMed ID: 18434630
[TBL] [Abstract][Full Text] [Related]
8. Alternate endpoints for screening phase II studies.
Dhani N; Tu D; Sargent DJ; Seymour L; Moore MJ
Clin Cancer Res; 2009 Mar; 15(6):1873-82. PubMed ID: 19276273
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies for soft-tissue sarcomas.
Tap WD; Federman N; Eilber FC
Expert Rev Anticancer Ther; 2007 May; 7(5):725-33. PubMed ID: 17492935
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy in adult soft tissue sarcoma.
Jain A; Sajeevan KV; Babu KG; Lakshmaiah KC
Indian J Cancer; 2009; 46(4):274-87. PubMed ID: 19749457
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
[TBL] [Abstract][Full Text] [Related]
12. Clinical endpoints for drug development in prostate cancer.
Ramiah V; George DJ; Armstrong AJ
Curr Opin Urol; 2008 May; 18(3):303-8. PubMed ID: 18382240
[TBL] [Abstract][Full Text] [Related]
13. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
[No Abstract] [Full Text] [Related]
14. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
15. Regional hyperthermia in high-risk soft tissue sarcomas.
Issels RD
Curr Opin Oncol; 2008 Jul; 20(4):438-43. PubMed ID: 18525341
[TBL] [Abstract][Full Text] [Related]
16. Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304.
Tanaka K; Kawamoto H; Saito I; Yoshimura K; Fukuda H; Iwamoto Y
Jpn J Clin Oncol; 2009 Apr; 39(4):271-3. PubMed ID: 19155282
[TBL] [Abstract][Full Text] [Related]
17. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
Tascilar M; Loos WJ; Seynaeve C; Verweij J; Sleijfer S
Oncologist; 2007 Nov; 12(11):1351-60. PubMed ID: 18055856
[TBL] [Abstract][Full Text] [Related]
18. Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations.
Verweij J; Baker LH
Eur J Cancer; 2010 Mar; 46(5):863-8. PubMed ID: 20138507
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.
Chmielowski B; Federman N; Tap WD
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1217-28. PubMed ID: 23098121
[TBL] [Abstract][Full Text] [Related]
20. Role of chemotherapy in pediatric nonrhabdomyosarcoma soft-tissue sarcomas.
Ferrari A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):929-38. PubMed ID: 18533802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
